MarketCap
Facebook
X
Telegram
Navidea Biopharmaceuticals EPS Ratio | NAVB
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Navidea Biopharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.56 | -0.4 | -0.48 | -0.76 | -0.09 | 0.47 | -0.09 | -0.18 | -0.24 | -0.35 | -0.29 | 0.06 | -0.72 | -0.54 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.47 | -0.76 | -0.298 |
Quarterly EPS Ratio Navidea Biopharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.02 | 0.12 | -0.05 | - | -0.25 | -0.1 | -0.1 | - | -0.08 | -0.09 | -0.11 | - | -0.13 | -0.11 | -0.13 | - | -0.17 | -0.24 | -0.24 | - | -0.02 | -0.02 | -0.04 | -0.03 | -0.01 | -0.03 | 0.53 | -0.03 | -0.07 | -0.04 | -0.02 | -0.02 | -0.05 | -0.06 | -0.05 | -0.05 | -0.05 | -0.07 | -0.08 | -0.1 | -0.09 | -0.09 | -0.06 | -70 | -0.09 | -0.06 | -0.07 | - | 0.21 | -0.02 | -0.05 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.53 | -70 | -1.61 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
4.52 | $ 51.7 | 1.83 % | $ 1.5 B |  USA |
 |
Allakos
ALLK
|
-1.3 | - | - | $ 28.6 M | USA |
 |
Bicycle Therapeutics plc
BCYC
|
-3.16 | $ 3.73 | 3.61 % | $ 258 M |  Britain |
 |
Black Diamond Therapeutics
BDTX
|
0.39 | $ 1.89 | 0.53 % | $ 107 M | USA |
 |
Clovis Oncology
CLVS
|
-0.5 | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-2.33 | - | - | $ 401 M | USA |
 |
Rezolute
RZLT
|
-0.75 | $ 3.94 | 1.87 % | $ 299 M | USA |
 |
Evelo Biosciences
EVLO
|
-1.31 | - | -14.46 % | $ 27.9 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-0.01 | $ 2.52 | 1.17 % | $ 6.21 B |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
1.82 | $ 61.35 | 0.06 % | $ 11.8 B | USA |
 |
Benitec Biopharma
BNTC
|
-0.98 | $ 9.64 | 0.46 % | $ 449 M | USA |
 |
BioNTech SE
BNTX
|
-4.7 | $ 99.26 | 0.81 % | $ 24 B |  Germany |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-1.5 | - | - | $ 384 M | Britain |
 |
Genocea Biosciences
GNCA
|
-0.48 | - | -15.0 % | $ 3.04 M | USA |
 |
Burford Capital Limited
BUR
|
0.29 | $ 3.63 | 3.93 % | $ 795 M | Britain |
|
Amryt Pharma plc
AMYT
|
-0.66 | - | - | $ 621 M | Britain |
 |
G1 Therapeutics
GTHX
|
-0.93 | - | - | $ 370 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-5.97 | $ 2.17 | 0.46 % | $ 3.57 M | Israel |
 |
Catalyst Biosciences
CBIO
|
0.06 | $ 14.24 | 0.35 % | $ 1.27 B | USA |
 |
C4 Therapeutics
CCCC
|
-1.27 | $ 3.03 | 0.3 % | $ 251 M | USA |
 |
Codexis
CDXS
|
-0.5 | $ 1.37 | 1.45 % | $ 119 M | USA |
 |
Cerus Corporation
CERS
|
-0.08 | $ 2.61 | 0.38 % | $ 497 M | USA |
 |
AbbVie
ABBV
|
1.02 | $ 265.12 | 0.09 % | $ 469 B | USA |
 |
Humanigen
HGEN
|
-0.79 | - | -81.12 % | $ 4.28 M | USA |
 |
Coherus BioSciences
CHRS
|
1.43 | $ 1.17 | 1.48 % | $ 137 M | USA |
 |
AbCellera Biologics
ABCL
|
-0.49 | $ 12.65 | 2.76 % | $ 3.78 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
1.34 | $ 5.43 | 2.65 % | $ 288 M | USA |
 |
Celldex Therapeutics
CLDX
|
-3.9 | $ 31.48 | 1.16 % | $ 2.09 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-0.94 | $ 4.12 | 1.98 % | $ 50.3 M | Israel |
 |
Cellectar Biosciences
CLRB
|
-8.35 | $ 2.08 | 0.48 % | $ 5.43 M | USA |
 |
IGM Biosciences
IGMS
|
-3.24 | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
-4.55 | - | - | $ 13.1 M | Canada |
 |
Kinnate Biopharma
KNTE
|
-2.42 | - | - | $ 123 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-2.84 | - | - | $ 231 M | USA |
 |
Karuna Therapeutics
KRTX
|
-11.7 | - | - | $ 12.2 B | USA |
 |
Cocrystal Pharma
COCP
|
-0.78 | $ 1.15 | 1.67 % | $ 13 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-4.95 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Collegium Pharmaceutical
COLL
|
0.54 | $ 22.64 | 0.85 % | $ 717 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
0.95 | $ 118.51 | 4.93 % | $ 12.3 B | USA |
 |
Chimerix
CMRX
|
-0.99 | - | - | $ 756 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-5.9 | $ 7.45 | 0.19 % | $ 99.2 M | USA |
 |
Curis
CRIS
|
-0.58 | $ 0.88 | 0.85 % | $ 11.6 M | USA |
 |
CorMedix
CRMD
|
2.25 | $ 7.77 | 1.04 % | $ 560 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-6.47 | $ 55.7 | 0.23 % | $ 5.01 B |  Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
-0.19 | $ 11.8 | 8.21 % | $ 932 M | USA |
|
Champions Oncology
CSBR
|
-0.08 | $ 4.95 | 0.38 % | $ 68.5 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-0.17 | $ 4.88 | 0.62 % | $ 935 M | Canada |
 |
Cue Biopharma
CUE
|
-0.28 | $ 32.85 | 3.6 % | $ 3.11 B | USA |
 |
CEL-SCI Corporation
CVM
|
-0.87 | $ 1.72 | 2.38 % | $ 13.8 M | USA |